The FDA on Thursday granted accelerated approval to Amgen’s bispecific T cell engager tarlatamab in small cell lung cancer, an aggressive disease that makes up roughly 10% to 15% of lung cancer cases.
It’s the first bispecific T cell engager to be approved for a major…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
